 | | Vol. 13.45 – 16 November, 2021 |
| |
|
|
| Using an immune “hot” mouse ovarian cancer model, scientists found that cancer-associated-MSCs drove CD8+ T cell tumor immune exclusion and reduced response to anti–PD-L1 immune checkpoint inhibitor via secretion of numerous chemokines.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors used a tripartite model of human hepatocellular carcinoma cell line and MSCs co-cultured with peripheral blood mononuclear cells to investigate the impact of tumor and stromal cell interactions to the development of immunosuppressive tumor microenvironment.
[Frontiers in Cell and Developmental Biology] |
|
|
|
| Investigators compared the potential of human bone marrow MSCs cultured as 2D monolayers or 3D spheroids encapsulated in constructs of 3D-printed poly-L-lactide-co-trimethylene carbonate scaffolds and modified human platelet lysate hydrogels for bone regeneration.
[Stem Cell Research & Therapy] |
|
|
|
| Researchers tested if MSC secretome preserved myocardial transcriptome profile and whether MSC secretome from a certain source provided the optimal protection in donor hearts during cold storage.
[Journal of Molecular and Cellular Cardiology] |
|
|
|
| Scientists isolated radiation-induced senescent tdTOMp16 positive MSCs, established their absence of cell division, then measured levels of irradiation-induced expression of biomarkers of senescence by RNA-seq analysis.
[Cell Death Discovery] |
|
|
|
| Using cultured mesenchymal and cancer cells, as well as mouse allograft models, the authors provide evidence that extracellular lactate could be utilized by fibroblasts to maintain tricarboxylic acid cycle anaplerosis and non-essential amino acid biosynthesis through pyruvate carboxylase activity.
[Nature Metabolism] |
| |
|
|
| Deletion of the apoptotic effectors BAK and BAX prevented MSC death and attenuated their immunosuppressive effects in disease models used to define MSC potency.
[Nature Communications] |
|
|
|
| To identify the possible role of m6A binding protein YTHDF1 in human bone marrow MSCs osteogenesis in vivo, investigators constructed Ythdf1 knockout mice and showed that depletion of Ythdf1 would result in decreased bone mass in vivo.
[Cell Death & Disease] |
|
|
|
| MSCs were genetically modified to overexpress placental growth factor, and their effects on macrophage proliferation and polarization were analyzed in vitro in a transwell co-culture system, as well as in vivo in a mouse model for spinal fusion.
[Laboratory Investigation] |
|
|
|
| Scientists determined the effect of transplanting rat cranial bone-derived MSCs (rcMSCs) in rat spinal cord injury models. The transplantation of rcMSCs improved motor function and electrophysiology recovery, and reduced cavity ratio.
[Scientific Reports] |
|
|
|
| The authors investigated the utility of two human 3D bone marrow (BM) models for micronucleus (MN) assessment. Prednisolone induced MN in both 3D BM models, suggesting recapitulation of the in vivo microenvironment.
[Scientific Reports] |
|
|
|
| Researchers identified a role for MSC-extracellular vesicles in immune modulation and cellular salvage in a model of SARS-CoV-2 induced acute lung injury using pulmonary epithelial cells and exposure to cytokines or the SARS-CoV-2 receptor binding domain.
[PLoS One] |
|
|
|
|
| In recent years, the application of MSCs in rheumatic diseases has received increasing attention. The authors review the clinical progress in MSC application for the treatment of rheumatic diseases.
[Stem Cell Research & Therapy] |
|
|
|
| Stem cells, exosomes, and biomimetic materials represent emerging technologies for osteoporosis treatment. Scientists review the latest developments in these three aspects.
[Cellular & Molecular Biology Letters] |
|
|
|
|
| Rakovina Therapeutics, Inc. announced that the company has been selected to join a three-year US $975,000 research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma.
[Rakovina Therapeutics, Inc.] |
|
|
|
|
| February 2 – 6, 2022
Salt Lake City, Utah, United States |
|
|
|
|
|
| | Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
| NUI Galway – Galway, Ireland |
|
|
|
| | The University of Sheffield – Sheffield, England, United Kingdom |
|
|
|
| | The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
